Author
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Nov. 30, 2022—Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and contributions to pharmacology and to the ASPET organization.
Lab-to-Table Conversation: ‘The Impact of Obesity on Health’ Nov. 30
Nov. 22, 2022—Obesity is a well-known risk factor for diseases such as heart disease, cancer and diabetes. However, it is often considered to be a risk factor brought on by choice, or by inaction. This stigma, in combination with body image norms, oversimplifies obesity as it also complicates how individuals and society engage in discussions or interventions....
Vanderbilt’s Monteggia and Kavalali are awarded the Anna-Monika Prize
Nov. 18, 2022—Lisa Monteggia, Barlow Family Director of the Vanderbilt Brain Institute and professor of pharmacology, and Ege Kavalali, chair of the Department of Pharmacology and William Stokes Professor of Experimental Therapeutics, have been awarded the first prize by the Anna-Monika Foundation. The Anna-Monika Prize is an international award presented to researchers who have made significant advances...
Gastric Cancer Foundation funds Eunyoung Choi research
Nov. 18, 2022—The Gastric Cancer Foundation has awarded a one-year $100,000 research grant to Eunyoung Choi, PhD, assistant professor of Surgery in the Section of Surgical Sciences, to support her efforts to find a way to disrupt the transformation of dysplastic stem cells into stomach cancer. The award was one of two grants announced last month by...
Hawiger still blazing a trail in inflammation research
Nov. 18, 2022—Fifty-five years after he arrived at Vanderbilt University Medical Center, Jacek Hawiger, MD, PhD, Louise B. McGavock Professor and distinguished professor of Medicine, continues to blaze a trail through the wilderness of inflammation. His group’s latest finding, published Nov. 7 in the journal Scientific Reports, describes a new investigational peptide drug that can penetrate immune...
Vanderbilt, international collaborators discover treatment to slow neurodegenerative diseases
Nov. 15, 2022—Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work to a study that has identified a new treatment for previously untreatable dementias, including Alzheimer’s disease. Many...
Basic Sciences mourns the loss of Reynolds
Nov. 15, 2022—By Leah Mann Albert “Al” Reynolds, celebrated and respected professor of pharmacology, emeritus, passed away earlier in November. He had retired in August after 26 years at Vanderbilt University. In the nearly three decades of Reynolds’ affiliation with Vanderbilt, he established himself not only as an expert in cancer research, but also as an academician...
Weight cycling worsens the body’s ability to control glucose levels
Nov. 14, 2022—By Caroline Cencer The laboratory of Professor of Molecular Physiology and Biophysics Alyssa Hasty recently published a study stressing the importance of glucose homeostasis in maintaining healthy body function. While examining blood glucose levels in diet-induced obese mice, co-first authors Nathan Winn and Matthew Cottam, a postdoctoral fellow and a recent graduate, respectively, discovered that...
Gene mutations impair gut barrier
Nov. 10, 2022—All of us suffer from gastrointestinal (GI) distress from time to time, but people with mutations in the SLC12A2gene suffer from chronic GI infections, intestinal obstruction, constipation, nutrient malabsorption and blood in the intestine. To understand why this mutation causes such intense GI distress, Eric Delpire, PhD, and team used human epithelial colon cells to...
Alzheimer’s risk factor and cognition
Nov. 10, 2022—A genetic variant of apolipoprotein E (APOE), a protein involved in fat metabolism, is the strongest common genetic risk factor for Alzheimer’s disease (AD) and contributes to worse cognition in older adults. However, many people who have the variant (APOE-e4) remain cognitively normal as they age, suggesting there may be neuroprotective modifiers of APOE effects. ...